Reactome: A Curated Pathway Database
THIS SITE IS USED FOR CURATION AND TESTING
IT IS NOT STABLE, IS LINKED TO AN INCOMPLETE DATA SET, AND IS NOT MONITORED FOR PERFORMANCE. WE STRONGLY RECOMMEND THE USE OF OUR PUBLIC SITE

Query author contributions in Reactome

Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.

If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.

Name Email address

Details on Person Cysmethnil is a small molecule inhibitor of ICMT that has be...

Class:IdSummation:9656537
_displayNameCysmethnil is a small molecule inhibitor of ICMT that has be...
_timestamp2019-08-02 15:41:37
created[InstanceEdit:9656536] Rothfels, Karen, 2019-08-02
textCysmethnil is a small molecule inhibitor of ICMT that has been shown to reduce proliferation of cancer cell lines by promoting apoptosis (Winter-Vann et al, 2005; Wang et al, 2010; Judd et al, 2011; Sun et al, 2016; Manu et al, 2017). Cysmethynil is a poor candidate for clinical trials due to low solubility and other physical characteristics. A number of related small molecule inhibitors with improved physical properties are under investigation (Lau et al, 2014; Ramanujulu et al, 2013).
(summation)[Reaction:9656775] Cysmethynil binds ICMT:Zn2+ [Homo sapiens]
[Change default viewing format]
No pathways have been reviewed or authored by Cysmethnil is a small molecule inhibitor of ICMT that has be... (9656537)